Relationship of apparent diffusion coefficient to survival for patients with unresectable primary hepatocellular carcinoma after chemoembolization

Immediate post‐doxorubicin drug‐eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study

“…On the contrary, lesions with higher ADC are likely more aggressive in nature, with areas of necrosis at baseline. 23,42,51 Our study showed that a 20% increase in ADC values of HCC lesions immediately post-DEB-TACE predicted objective response at 1 month with no significant change at 3 months. Furthermore, lesions with objective response demonstrated a statistically significant increase in ADC at 1 month that continued to increase at 3 months.…”

“…The pretreatment ADC value of HCC has shown utility in predicting response to cTACE 23,42,51 and DEB-TACE, 52 demonstrating that lower pretreatment ADC values are more likely to respond to cTACE/DEB-TACE. It is postulated that lesions with a high degree of vascularity have more restricted diffusion (ie, lower ADC) making them a more ideal target for intraarterial therapy such as DEB-TACE.…”

Chemoembolization for Hepatocellular Carcinoma: 1-Month Response Determined with Apparent Diffusion Coefficient Is an Independent Predictor of Outcome

“…In our study, only 11.8% of nonresponders according to lowest ADC ratio and none of the responders according to average ADC ratio had long-term PFS, even after a second TACE treatment. Similarly, a recent study that included 23 patients showed that patients with greater ADC changes 24 hours after chemoembolization had significantly better overall cumulative survival compared with patients with limited increases in ADC (24). In another study, a significantly increased ADC ratio at 5-7 days was predictive for stable disease or partial remission 3 months after TACE, whereas a significantly lower ADC ratio was predictive of tumor relapse after 3 months (20).…”

Whole-body PET/MRI in oncology: current status and clinical applications

“…FDG PET/CT has been shown to improve response assessment in several tumor types ranging from malignant lymphoma to a variety of solid tumors [67,68]. In recent years, clinical studies have demonstrated that mid-treatment diffusion-weighted imaging could be used as an imaging response biomarker [69][70][71][72]. In the context of integrated PET/MRI, the addition of fMRI would enhance the performance of both modalities in the evaluation of both treatment response and recurrences.…”